For the period (end-December 31), Bruker had revenues of $627.5 million (518.1 million euros), up from the $599 million (494.5 million euros) posted in the fourth quarter of 2019. Organic revenue dipped by 0.4%, however.

Bruker Scientific Instruments produced $574.7 million (474.5 million euros) in the fourth quarter, up 5.1% overall compared with the same period a year ago. Organic revenue was approximately flat, according to the firm. Meanwhile, Bruker Energy & Supercon Technologies reported $54.7 million (45.2 million euros) in fourth-quarter revenues, down 5.2% overall and down 6.8% organically compared with the fourth quarter of 2019.

Bruker had fourth-quarter net income of $68.9 million (56.9 million euros), compared with $68.6 million (56.6 million euros) in the same period last year.

For the year, Bruker had $1.988 billion (1.641 billion euros) in revenue, down 4.1% overall and down 6% organically compared with the $2.072 billion (1.711 billion euros) in revenue generated in 2019. Net income for the year reached $157.8 million (130.3 million euros), compared with $197.2 million (162.8 million euros) last year. Profitability was hurt by lower revenues during the COVID-19 pandemic and related economic slowdown, according to the company.

Looking ahead, Bruker said it expects strong revenue growth, operating margin expansion, and earnings per share growth in 2021.

Bruker launches Vutara superresolution microscope
Bruker has announced the launch of the Vutara VXL superresolution fluorescence microscope for use in nanoscale biomedical imaging.

Bruker supports COVID19-NMR Consortium
Bruker is highlighting its support of a global project called COVID19-NMR that will investigate the structure, dynamics, function, and binding of SARS-CoV-2...

Bruker releases MALDI-2 to advance mass spectrometry
Bruker announced a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world's first commercial MALDI-2 postionization...